Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, the rest of Asia, and internationally. 

It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. 

Takeda Pharmaceutical Company Limited has an out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., ZEDIRA GmbH, and Dr Falk Pharma GmbH, as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreements with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. 

Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

Takeda Pharmaceuticals was founded in 1781 and was incorporated on January 29, 1925. One of the firm's mainstay drugs is Actos, a compound in the thiazolidinedione class of drugs used in the treatment of type 2 diabetes. It was launched in 1999. 

In 1977, Takeda first entered the U.S. pharmaceutical market by developing a joint venture with Abbott Laboratories called TAP Pharmaceuticals. Through TAP Pharmaceuticals Takeda and Abbott launched blockbuster drugs Lupron, in 1985, and then Prevacid, in 1995. In 2001, TAP's illegal marketing of Lupron resulted in both civil and criminal charges by the U.S. Department of Justice and the Illinois attorney general for federal and state medicare fraud. TAP was fined $875 million, then reported as the largest pharmaceutical settlement in history.

In February 2005, Takeda acquired San Diego, California, based Syrrx, a company specializing in high-throughput X-ray crystallography, for US$270 million. In February 2008, Takeda acquired the Japanese operations of Amgen and rights to a dozen of the California biotechnology company's pipeline candidates for the Japanese market. In April, Takeda acquired Millennium Pharmaceuticals of Cambridge, Massachusetts, a company specializing in cancer drug research, for US$8.8 billion. The acquisition brought in Velcade, a drug indicated for haematological malignancies, as well as a portfolio of pipeline candidates in the oncology, inflammation, and cardiovascular therapeutic areas. Millennium now operates as an independent subsidiary. In May, the company licensed non-exclusively the RNAi technology platform developed by Alnylam Pharmaceuticals, creating a potential long-term partnership between the companies.

In March 2008, Takeda and Abbott Laboratories announced plans to conclude their 30-year-old joint venture, TAP Pharmaceuticals. The split resulted in Abbott acquiring U.S. rights to Lupron and the drug's support staff. Takeda received rights to Prevacid and TAP's pipeline candidates. The move also increased Takeda's headcount by 3,000 employees.

In September 2011, Takeda acquired Nycomed for €9.6 billion. In May 2012, Takeda purchased Brazilian pharmaceutical company Multilab for R$540 million. In June, Takeda announced it would acquire URL Pharma, then run by the founder's son Richard Roberts, for US$800 million. In September 2014, Takeda announced it would team up with BioMotiv to identify and develop new compounds over a five-year period, worth approximately US$25 million. On 30 September 2014, Takeda announced it would expand collaboration with MacroGenics, valued at up to US$1.6 billion. The collaboration focused on the co-development of the preclinical autoimmune compound MGD010. MGD010 is a therapy which targets the B-cell surface proteins CD32B and CD79B and is indicated for lupus and rheumatoid arthritis.

In 2015, Takeda sold its respiratory drugs business to AstraZeneca for $575 million, which included roflumilast and ciclesonide. In November, the U.S. Food and Drug Administration approved Ixazomib developed by Takeda for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma after at least one prior therapy. In December 2016, the company spun out its neuroscience research division into Cerevance, a joint venture along with Lightstone Ventures. In February 2017, Takeda acquired Ariad Pharmaceuticals for $5.2 billion, expanding the company's oncology and haematology divisions. 

In January 2018, the company acquired stem cell therapy developer TiGenix for up to €520 million. In January 2019, Takeda acquired Shire for more than US$50 billion. In October, Takeda announced it had sold a portfolio of over-the-counter and prescription medicines in the Middle East and Africa to Swiss pharmaceuticals company Acino International for more than $200 million. In January 2020, Takeda announced a research partnership with the Massachusetts Institute of Technology to advance discoveries in artificial intelligence and health. The MIT-Takeda Program is housed in the MIT Jameel Clinic and is led by Professor James J. Collins, with a steering committee led by Professor Anantha P. Chandrakasan, dean of the MIT School of Engineering, and Anne Heatherington, senior vice president and head of Data Sciences Institute at Takeda. 

In March 2020, Takeda announced that it has entered into an exclusive agreement to divest a portfolio of non-core products in Latin America to Hypera S.A. for a total value of $825 million. In March 2021, the company announced it would acquire Maverick Therapeutics, Inc. and its two major programs TAK-186 in trials for the treatment of EGFR-expressing tumours and TAK-280 for use in the treatment of patients with B7H3-expressing tumours. In October, they acquired GammaDelta Therapeutics and its gamma delta T cell immunotherapy programme. In January 2022, Takeda announced it would exercise its option to acquire Adaptate Biotherapeutics and its antibody-based T-cell technology, reuniting Adaptate and its former parent company, GammaDelta Therapeutics, in a single organisation.

The mission of Takeda Pharmaceutical is to strive towards better health for people worldwide through leading innovation in medicine. Takeda is committed to improving the health of patients through the discovery, development, and delivery of innovative medicines and therapies for a wide range of medical conditions.

Takeda believes in putting patients at the center of everything they do, and its mission reflects this commitment. The company aims to create value for patients by developing and delivering innovative, high-quality medicines and therapies that address unmet medical needs.

Takeda also recognizes the importance of social responsibility and environmental sustainability. The company aims to create a sustainable future by integrating sustainable practices into its operations and by promoting environmental stewardship throughout its value chain.

Takeda Pharmaceutical has a vision to become a leading global biopharmaceutical company focused on delivering innovative and life-changing treatments to patients worldwide. Their vision is centered on five key areas:

Patient-centricity: Takeda is committed to putting patients at the center of everything they do, from research and development to commercialization and beyond.

Innovation: Takeda is dedicated to developing innovative therapies that address unmet medical needs and improve patients' lives.

Global presence: Takeda's vision is to have a strong global presence, with a broad portfolio of products that address a range of diseases and conditions.

Corporate responsibility: Takeda is committed to being a responsible corporate citizen and contributing to the health and well-being of communities worldwide.

Talent development: Takeda recognizes that its success depends on the skills, expertise, and dedication of its employees. Their vision is to attract, develop, and retain the best talent in the industry.

Prescription medications: Takeda develops and sells prescription medications for a wide range of medical conditions, including cardiovascular disease, oncology, gastroenterology, immunology, and neuroscience.

Over-the-counter (OTC) medications: Takeda offers a range of OTC medications, including pain relievers, digestive aids, and cough and cold remedies.

Vaccines: Takeda develops and distributes vaccines for a variety of infectious diseases, including dengue fever, Zika virus, and norovirus.

Plasma-derived therapies: Takeda produces plasma-derived therapies for the treatment of bleeding disorders, immunodeficiency diseases, and alpha-1 antitrypsin deficiency.

Biosimilars: Takeda produces biosimilar versions of existing biologic drugs for the treatment of conditions such as cancer and rheumatoid arthritis.

Clinical research services: Takeda provides clinical research services to support the development of new medications and therapies.

Digital health solutions: Takeda offers a range of digital health solutions, including mobile apps and wearable devices, to help patients manage their health and wellness.